/Investors

i&i Biotech Fund

Venture capital

Luxembourg · Pre-Seed–Series B · 9 people tracked

Find your way into i&i Biotech Fund

164 people in our graph share verified history with the i&i Biotech Fund team — schools, employers, funds. One of them is your warm intro.

Simona Šandováunlockedknows Karel Kubias · together at i&i Biotech Fund (overlapped)
knows the team · via Člověk v tísni
knows the team · via Metro International
×2knows the team · via Merck Millipore, division of Merck KGaA
×7knows the team · via Smash Capital
✨ Fox Verdict
Sign up to see your fit

Investment thesis

i&i Bio backs Europe's next wave of early-stage life science startups that address unmet medical needs through strong science and a competitive edge. It seeks founders with a clear edge and ambition to take innovations global, and is willing to engage very early in a company's journey. The fund supports business creation from around €150k, with a sweet spot between €0.5M and €2M, and reserves possible follow-on funding for its best-performing portfolio. Its primary geographic focus is Central and Eastern Europe, though it works with teams across Europe. As a life sciences investor, it concentrates on drug discovery, medtech, diagnostics, and AI verticals.

Source: firm website, verified Sep 27, 2026.

Stage
Pre-Seed–Series B
Check
$150K – $2M
HQ
Luxembourg, LU
Instruments
Equity
Founded
2021
AUM
$48.6M
Tracked investments
19

Team · 9 people

from the firm's website & curated & public directories

What they invest in

from 17 of 19 portfolio companies

Biotech ×16Healthtech ×9Deep Tech ×6Medical Devices ×5AI & Machine Learning ×4Hardware ×2New Materials ×2Digital Health ×1

HQs:United States×3Czechia×2Germany×2United Kingdom×2Netherlands×2Spain×1

Investments · 19 tracked

founders shown can be your intro path

By year:2023 · 22022 · 24 dated

Sophomersophomer.comMar 2023✓ verified

Sophomer is a Czech biotech company developing in vitro diagnostics (IVD) products, working in partnership with academic labs on the design and synthesis of new polymers.

BiotechHealthtechMedical DevicesNew Materials

Martin Burkhard(Founder & Managing Director – CEO, Operations & Development)Jan Plicka(Founder and Inventor & Managing Director – R&D)Jiří Moos(Founder and Inventor & Managing Director, Business Development)inTomáš Etrych(Founder and Inventor & Sophomer's Partner Lab)Libor Kostka(Founder and Inventor & Sophomer's Partner Lab)Vladimír Šubr(Founder and Inventor & Sophomer's Partner Lab)

Co-investorsBiotech Investments S.R.O

Antiverse Seedantiverse.ioin𝕏

Antiverse is a techbio company that uses machine learning and cell line engineering to design de novo antibody therapeutics against difficult targets such as G-protein coupled receptors and ion channels.

AI & Machine LearningBiotechDeep TechCardiff, GB

Ben H.(Founder)in

Co-investorsCambridge Angels groupDeep Science VenturesDOMiNO VenturesFuture Planet CapitalInnospark VenturesTensor Ventures+1 more

CasInvent Pharmacasinvent.comin

CasInvent Pharma develops pharmaceutical solutions, currently raising Series A funding through a crowdfunding campaign.

BiotechHealthtech

Alexander Scheer(CEO)in

Co-investorsBiotech Investments S.R.OJIC VenturesKhanu

Deltadeltadevteam.comin𝕏May 2023

Delta Development Team manufactures temperature-controlled medical transport and storage devices, including smart blood coolers and autonomous refrigeration units, for healthcare facilities and blood banks.

HardwareHealthtechLogistics & Supply ChainMedical Devices

Co-investorsAggie Angel NetworkAZ Venture Capital Inc.Central Texas Angel NetworkOost NL

Delta Life Sciencedeltalifescience.com

Delta Life Science develops the inQuiQ, a label-free biosensing instrument that uses integrated photonics to measure biomolecular binding affinity and kinetics (KD, ka, kd) in real time from small sample volumes.

BiotechDeep TechHardware

Dracen Pharmaceuticalsdracenpharma.com

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.

BiotechHealthtechBaltimore, US

Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)

BoardJonathan Leff(Director)Robert Jackson(Director)

Co-investorsBiotech Investments S.R.OOUP (Osage University Partners)Deerfield Management CompanySofinnova Ventures

Enzyreenzyre.comNov 2022

Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.

BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL

Wim van den Broek(CEO)inWaander(CSO)

Co-investorsNovalis BiotechOost NLTakeda Ventures

Heartbeatheartbeat.bio

Heartbeat.bio develops cardiac chamber models (Cardioids) and an assay suite that characterize heart disease phenotypes at structural, functional, and molecular levels.

BiotechDeep TechHealthtech

iQure Pharmaiqurepharma.comin

iQure Pharma is a clinical-stage biotech developing astrocyte-targeted therapeutics that enhance EAAT2 to restore glutamate balance in central nervous system disorders such as epilepsy, Parkinson's disease, migraine, and ALS.

BiotechHealthtechSkillman, US

Peter Schiemann(Founder)inPawel Zolnierczyk(Executive Officer)in

Co-investorsKeiretsu ForumVentura BioMed Investors

KyDo Therapeuticskydo-tx.com

KyDo Therapeutics is a preclinical-stage biotechnology company developing novel covalent-allosteric small molecule inhibitors intended to become best-in-class oncology drugs.

AI & Machine LearningBiotechDortmund, DE

Co-investorsKhanu

LAM-Xlamxnano.com

LAM-X develops advanced nanofiber and polymer materials, including light-activated antimicrobial textiles and Western Blot membranes, for applications in medical devices, food packaging, crop protection, water filtration, and life science research.

BiotechMedical DevicesNew MaterialsZlatníky-Hodkovice, CZ

Nanoligentnanoligent.com

Nanoligent is a biotech spin-off of the Universitat Autònoma de Barcelona and Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau that uses protein engineering and nanobiotechnology to develop targeted drug therapies, with a first cancer candidate targeting the CXCR4 receptor to limit tumor growth and metastasis.

BiotechDeep TechMedical DevicesBarcelona, ES

Dr. A. Villaverde(Founder)Dr. E. Vázquez(Founder)Dr. R. Mangues(Founder)Dr. M. Rodríguez(Founder)

Sampling Humansamplinghuman.comin𝕏

Sampling Human develops systems to generate actionable insights from individual biology using cellular-resolution data collection technologies.

AI & Machine LearningBiotechHealthtech

Daniel Georgiev(Co-Founder, CEO, and Board Member)inHynek Kasl(Co-Founder and Head of Engineering)inMartin Cienciala(Co-Founder and Head of Innovation)in

Co-investorsB3 HoldingBiotech Investments S.R.O

T-CURXt-curx.com

T-CURX is a venture-backed biotechnology company developing autologous CAR-T cell therapies using proprietary non-viral technologies, including in vivo and bedside-manufactured CAR-T approaches based on T cell-targeted LNP delivery of Sleeping Beauty transposon vectors.

BiotechHealthtechWürzburg, DE

Michael Hudecek(Co-founder)Christoph Rader(Co-founder & Member of the Scientific Advisory Board)Ulf Grawunder(Co-founder & CEO)in

Co-investorsHighlight CapitalBioMedPartners

Ternary Tx Managed by: Oliver Sextonternarytx.co.uk

Ternary develops AI-driven drug discovery technology focused on targeted protein degradation and induced proximity platforms.

AI & Machine LearningBiotechDeep Tech

Chris Tame(CEO & Co-Founder)inAndrew Potterton(CTO & Co-Founder)in

Co-investorsPace VenturesUK Innovation & Science Seed Fund

THEOREMAtheorema.ai

Hynek Walner(Founder)

Co-investorsTilia Impact Partners

Vasa Therapeuticsvasatherapeutics.com

Vasa Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics that target the pathophysiology of cardiovascular aging.

BiotechLongevity

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Captain T Cell GmbHCeleris Therapeutics

Portfolio news

latest coverage across their companies

Frequently asked questions

How many investments has i&i Biotech Fund made?
i&i Biotech Fund has 19 tracked investments.
What stage does i&i Biotech Fund invest at?
i&i Biotech Fund invests at the Pre-Seed, Seed, Series A, Series B stages.
What is i&i Biotech Fund's typical check size?
i&i Biotech Fund typically writes checks of $150K – $2M.
What sectors does i&i Biotech Fund focus on?
i&i Biotech Fund focuses on AI & Machine Learning, Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
Where is i&i Biotech Fund located?
i&i Biotech Fund is headquartered in Luxembourg, LU.

Similar investors

Featured in lists